Doripenem for injection

Hospital Pharmacy

Volumn 43, Issue 3, 2008, Pages 210-221

  Cada, Dennis J ^c   Levien, Terri ^a   Mistry, Bhavin ^b   Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Deaconess Medical Center Spokane   (United States)

^c Washington State University Spokane ^*

Author keywords

[No Author keywords available]

Indexed keywords

CILASTATIN PLUS IMIPENEM; DORIPENEM; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; LIVER ENZYME; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; PROBENECID; VALPROIC ACID;

ABDOMINAL INFECTION; ANEMIA; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL MENINGITIS; BONE INFECTION; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DISTRIBUTION VOLUME; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STABILITY; DRUG SUBSTITUTION; ELECTROENCEPHALOGRAM; ENDOCARDITIS; GYNECOLOGIC INFECTION; HEADACHE; HOSPITAL INFECTION; HUMAN; INFECTIOUS ARTHRITIS; INJECTION; LOWER RESPIRATORY TRACT INFECTION; MYCOSIS; NAUSEA; NONHUMAN; PELVIC INFLAMMATORY DISEASE; PHLEBITIS; PNEUMONIA; PRURITUS; RASH; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SEPTICEMIA; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; THROMBOCYTOPENIA; THRUSH; TREATMENT RESPONSE; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; VULVA DISEASE;

EID: 67651151528     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4303-210     Document Type: Review

References (24)

1. Doribax [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc; 2007.
2. New drug application submitted for investigational antibiotic doripenem [press release]. Raritan, NJ: Johnson & Johnson; June 6, 2007. http://www.jnj.com/news/jnj-news/20070606-121447.htm. Accessed September 21, 2007.
3. New drug application submitted for investigational antibiotic doripenem [press release]. Raritan, NJ: Johnson & Johnson; December 15, 2006. http://www.jnj.com/news/jnj-news/20061215-103306.htm. Accessed September 21, 2007.
4. Primaxin IV [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2006.
5. Primaxin IM [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2005.
6. Merrem [package insert]. Wilmington, DE: AstraZeneca; 2007.
7. Invanz [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2007.
8. Jones RN, Huynh HK, Beidenbach DJ, Fristche TR, Sader HS. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemo. 2004;54(1):144-154.
9. Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet. 2000;39(3):185-201. (Pubitemid 30727388)
10. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs. 2007;67(7):1027-1052.
11. Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect. 2005;11(12):974-984.
12. Wexler HM, Engel AE, Glass D, Li C. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob Agents Chemother. 2005;49(10):4413-4417. (Pubitemid 41401003)
13. Chen Y, Garber E, Zhao Q, et al. In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother. 2005;49(6):2510-2511. (Pubitemid 40734491)
14. Huynh HK, Beidenbach DJ, Jones RN. Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside. Diagn Microbiol Infect Dis. 2006;55(3):241-243.
15. Van Wart S, Bhavnani SM, Phillips L, Wikler MA, Ambrose PG. Population pharmacokinetics (PPK) of doripenem (DOR) [poster]. 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; October 20-November 2, 2004; Washington, DC. Poster A-18.
16. Floren L, Wikler M, Kilfoil T, Ge Y. A phase I open-label controlled study to evaluate the safety, tolerability, and pharmacokinetics (PK) of doripenem (DOR) administered intravenously to subjects with renal impairment. 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; October 20-November 2, 2004; Washington, DC. Poster A-17.
17. Floren L, Wikler M, Kilfoil T, Ge Y. A phase I, double-blind, placebo-controlled study to determine the safety, tolerability, and pharmacokinetics (PK) of prolonged-infusion regimens of doripenem (DOR) in healthy subjects [abstract]. 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy: October 20-November 2, 2004: Washington, DC. Abstract A-16.
18. Malafaia O, Umeh O, Jiang J. Doripenem versus meropenem for the treatment of complicated intra-abdominal infections [poster]. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, CA. Poster L-1564b.
19. Solomkin JS, Umeh O, Jiang J, Kaniga K, Friedland I. Doripenem vs. meropenem with an option for oral step-down therapy in the treatment of complicated intra-abdominal infections [abstract]. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL. Abstract L-487.
20. Rea-Neto A, Neiderman M, Prokocimer P, et al. Efficacy and safety of intravenous doripenem vs. piperacillin/tazobactam in nosocomial pneumonia [abstract]. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL. Abstract L-731.
21. Clavel M, Prokocimer P, Lee M, et al. Efficacy of doripenem versus imipenem in patients with ventilator-associated pneumonia and high disease severity. 45th Annual Infectious Disease Society of America Meeting; October 4-7, 2007; San Diego, CA. Abstract 1081.
22. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of doripenem vs. imipenem for ventilator-associated pneumonia [abstract]. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL. Abstract L-486.
23. Horiuchi M, Kimura M, Tokumura M, Hasebe N, Arai T, Abe K. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology. 2006;222(1-2):114-124. (Pubitemid 44275125)
24. Nakajima Y, Mizobuchi M, Nakamura M, et al. Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab Dispos. 2004;32(12):1383-1391. (Pubitemid 39564558)